Sepracor gets FDA input on antidepressant plans
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sepracor is "evaluating the possible initiation" of a Phase III registrational trial for its serotonin/norepinephrine reuptake inhibitor SEP-227162, after hearing from FDA that the agency has agreed with key elements of Sepracor's plans. In 2008, the firm submitted a briefing package to the agency outlining a proposal to conduct an abbreviated Phase III program for the dual reuptake inhibitor. Sepracor has also fully enrolled a Phase II study for its novel triple reuptake inhibitor for depression, SEP-225289, with clinical results anticipated in the third quarter
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.